Experimental designs for phase I and phase I/II dose-finding studies

@article{Oquigley2006ExperimentalDF,
  title={Experimental designs for phase I and phase I/II dose-finding studies},
  author={J O'quigley and Sarah Zohar},
  journal={British Journal of Cancer},
  year={2006},
  volume={94},
  pages={609 - 613}
}
We review the rationale behind the statistical design of dose-finding studies as used in phase I and phase I/II clinical trials. We underline what the objectives of such dose-finding studies should be and why the widely used standard design fails to meet any of these objectives. The standard design is a ‘memoryless’ design and we discuss how this impacts on practical behaviour. Designs introduced over the last two decades can be viewed as designs with memory and we discuss how these designs are… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials.

Annals of oncology : official journal of the European Society for Medical Oncology • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 16 references

A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer

AM Bos, FY De Vos, +6 authors PH Willemse
Eur J Cancer 41: • 2005
View 1 Excerpt

Operating characteristics of the standard phase I clinical trial design

E Reiner, X Paoletti, J O’Quigley
Comput Stat Data Anal 30: • 1999
View 1 Excerpt

Similar Papers

Loading similar papers…